ERBC-closeup-scientist-tube

Discovery

Discovery Services

At ERBC, we provide a broad range of Discovery Services designed to accelerate the development of innovative therapies. Our team combines cutting-edge technologies with extensive expertise to support every stage of drug development, from early discovery to preclinical validation. We specialize in offering integrated, scientifically robust solutions tailored to the needs of our clients across multiple therapeutic areas.

Our Key Discovery Services Include:

CellDX and PDX Models

ERBC leverages innovative CellDX (cancer cell line derived Xenograft) and PDX (Patient-Derived Xenograft) models to accelerate cancer research and therapy development. Our AVI-cellDXTM AVI-PDX™ model, developed using avian embryos, enables rapid tumor formation and therapeutic evaluation, within a week. The model creates miniature, patient-specific tumors within the embryo, providing a powerful tool for drug testing and comparison with SOC. Tumorigenesis is targeted through orthotopic implantation in tissues homologous to those in which primary tumors develop or where metastasis is known to occur, ensuring high relevance and accuracy. Utilizing state-of-the- art 3D lightsheet imaging and molecular analysis capabilities, we are able to track tumor progression, monitor treatment efficacy, and explore molecular profiles that inform therapeutic decisions.
Learn more Learn more
CellDX and PDX Models

Preclinical POC

Our Preclinical Proof of Concept (POC) studies are designed to demonstrate the therapeutic potential of your candidates before clinical trials. Through the application of preclinical models, including non-human primates and rodents, we provide clear evidence of your drug’s efficacy in relevant biological systems, giving you confidence before moving forward with clinical trials.
Learn more Learn more
Preclinical POC

Early safety

To detect potential safety risks at an early stage, ERBC conducts Early Safety evaluations, which combine in vitro and in vivo toxicity assays across rodent and non-rodent species. These studies, including exploratory safety programs and predictive biomarkers, help identify adverse effects such as mutagenicity, cardiovascular toxicity, or neurological impacts. Through optimized study designs and reduced animal numbers, we achieve low-cost, high-quality results. Reports are delivered within two weeks of the final experimental phase, ensuring quick decision-making.
Learn more Learn more
Early safety

Efficacy

Our Efficacy Studies are designed to assess the therapeutic potential of your compounds. We use advanced models and techniques, including non-invasive imaging, to track the progression of diseases like cancer or infections in real-time and measure the effectiveness of treatments.
Learn more Learn more
Efficacy

Tolerability

At ERBC, we perform comprehensive tolerability studies to evaluate the safety profile of your compounds in early drug development. Our studies help identify the tolerated dose of a compound, ensuring that it is safe for progression to clinical trials. We conduct these studies across a range of species, including rodents and non-rodents, to assess both single and repeated administrations of the compound.
Learn more Learn more
Tolerability

ADME, PK, PD, Biodistribution

Absorption, Distribution, Metabolism, and Excretion (ADME) studies, along with biodistribution analysis, help determine the pharmacokinetics of your compounds and their behavior within the body, providing key insights into their efficacy and safety profiles. ERBC performs comprehensive biodistribution studies using cutting-edge, non-invasive in vivo fluorescence imaging. This advanced technique allows us to track the distribution and retention of your compounds in living animals over time. Unlike traditional pharmacokinetics (PK) studies, which are typically conducted at terminal endpoints, our in vivo fluorescence imaging provides real-time insights into the biodistribution of various substances, including nanoparticles, nanomaterials, proteins, antibodies, and liposomes.
Learn more Learn more
ADME, PK, PD, Biodistribution

BSL2, BSL3

ERBC maintains accredited BSL-2 and BSL-3 animal facilities, totaling 400 m², to safely conduct research involving infectious agents requiring moderate to high containment. These facilities are equipped to house a diverse range of small animal species.
Learn more Learn more
BSL2, BSL3

Imaging

At ERBC, we offer advanced Imaging Platforms that enhance our ability to analyze and track complex biological processes in real-time, across various model systems. These platforms enable detailed insights into drug efficacy, disease progression, and tissue-specific responses to treatment, ensuring better data quality and more informed decision-making.
Learn more Learn more
Imaging